Top-Rated StocksTop-RatedNASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free TSHA Stock Alerts $2.16 +0.12 (+5.87%) (As of 06/27/2024 ET) Add Compare Share Share Today's Range$2.04▼$2.2150-Day Range$2.04▼$4.1752-Week Range$0.57▼$4.32Volume3.69 million shsAverage Volume2.56 million shsMarket Capitalization$404.89 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Taysha Gene Therapies alerts: Email Address Taysha Gene Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside214.1% Upside$6.80 Price TargetShort InterestHealthy7.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector409th out of 916 stocksBiological Products, Except Diagnostic Industry56th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.87% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 8.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 2.4 News and Social Media Coverage News SentimentTaysha Gene Therapies has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to remain at ($0.43) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Taysha Gene Therapies Stock (NASDAQ:TSHA)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More TSHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Stock News HeadlinesJune 26 at 9:14 AM | globenewswire.comTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 26 at 8:36 AM | investorplace.comWhy Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?June 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 26 at 7:36 AM | benzinga.comWorthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionJune 25 at 6:34 PM | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 22, 2024 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.1%June 22, 2024 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Given "Market Outperform" Rating at JMP SecuritiesJune 20, 2024 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor FitzgeraldJune 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 19, 2024 | seekingalpha.comTaysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead RockyJune 19, 2024 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Receives "Buy" Rating from Chardan CapitalJune 18, 2024 | benzinga.comWhat's Going On With Taysha Gene Therapies Stock Tuesday?June 18, 2024 | globenewswire.comTaysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett SyndromeJune 17, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)June 13, 2024 | investorplace.comHow to Invest in Penny Stocks in 2024: 3 Best PicksJune 12, 2024 | globenewswire.comTaysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific MeetingJune 7, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | insidermonkey.comIs Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?May 28, 2024 | markets.businessinsider.comBreaking Down Taysha Gene Therapies: 16 Analysts Share Their ViewsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA SupportMay 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)May 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chemed (CHE), Acadia Healthcare (ACHC) and Taysha Gene Therapies (TSHA)May 14, 2024 | investorplace.comTSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | msn.comTaysha Gene Therapies upgraded at Jefferies on Rett Syndrome assetMay 14, 2024 | globenewswire.comTaysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | msn.comTaysha Gene Therapies Q1 2024 Earnings PreviewMay 7, 2024 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14See More Headlines Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees52Year Founded2020Price Target and Rating Average Stock Price Target$6.80 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+214.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,570,000.00 Net Margins-833.60% Pretax Margin-833.60% Return on Equity-782.81% Return on Assets-55.24% Debt Debt-to-Equity Ratio0.75 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$14.16 million Price / Sales28.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book5.41Miscellaneous Outstanding Shares187,018,000Free Float181,969,000Market Cap$404.89 million OptionableOptionable Beta0.50 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 56)CEO & Chairman Comp: $925.33kDr. Sukumar Nagendran M.D. (Age 57)President, Head of Research & Development and Director Comp: $820.59kMr. Kamran Alam CPA (Age 46)M.B.A., CFO & Corporate Secretary Comp: $573.36kHayleigh CollinsDirector of Corporate Communications & Investor RelationsMs. Tracy M. Porter SPHRChief People OfficerMr. Frederick Porter Ph.D.Chief of Staff & Technical Operations OfficerMs. Emily McGinnis M.P.H.Chief Patient Advocacy & External Affairs OfficerMr. Sean McAuliffeChief Business OfficerDr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy ProgramBerge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy ProgramMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKVaxartNASDAQ:VXRTAthira PharmaNASDAQ:ATHATCR2 TherapeuticsNASDAQ:TCRRPassage BioNASDAQ:PASGView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Sold 7,600,000 shares on 5/17/2024Ownership: 5.814%Artal Group S.A.Bought 24,444 shares on 5/17/2024Ownership: 1.972%Avoro Capital Advisors LLCBought 14,294,445 shares on 5/15/2024Ownership: 9.972%Price T Rowe Associates Inc. MDSold 128,004 shares on 5/15/2024Ownership: 0.588%EntryPoint Capital LLCSold 168,711 shares on 5/14/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions TSHA Stock Analysis - Frequently Asked Questions Should I buy or sell Taysha Gene Therapies stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks. What is Taysha Gene Therapies' stock price target for 2024? 10 Wall Street analysts have issued 1 year target prices for Taysha Gene Therapies' shares. Their TSHA share price targets range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.80 in the next year. This suggests a possible upside of 214.1% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts. How have TSHA shares performed in 2024? Taysha Gene Therapies' stock was trading at $1.77 at the beginning of the year. Since then, TSHA shares have increased by 22.3% and is now trading at $2.1650. View the best growth stocks for 2024 here. When is Taysha Gene Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TSHA earnings forecast. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to analysts' expectations of $3.70 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter in the prior year, the company posted ($0.28) EPS. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (9.97%), RA Capital Management L.P. (5.81%), Vanguard Group Inc. (3.16%), Artal Group S.A. (1.97%), Price T Rowe Associates Inc. MD (0.59%) and StemPoint Capital LP (0.58%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSHA) was last updated on 6/27/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhere AI is REALLY Going NextBuying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.